Bill Parr

Bill Parr is a 28-year pharmaceutical veteran currently serving as the Director of Asset Innovation Evaluation and Portfolio Planning at CSL Behring. They have a comprehensive background in drug development, life cycle planning, and global commercialization, with expertise in Rare Disease, Inflammation/Immunology, and Gene Therapy from involvement in over 180 clinical development programs. Bill's career includes significant roles at Pfizer, Wyeth Pharmaceuticals, and The SEARLE Company, along with early experience as a Diagnostic Sales Specialist at Abbott Diagnostics and as a MEDEVAC pilot in the US Army. Bill obtained a Master of Business Administration from DePaul University after earning a Bachelor of Science in Business Administration from the University of Arkansas.